Marotta, Serena
Marano, Luana
Ricci, Patrizia
Cacace, Fabiana
Frieri, Camilla
Simeone, Luigia
Trastulli, Fabio
Vitiello, Selenia
Cardano, Flora
Pane, Fabrizio
Risitano, Antonio M http://orcid.org/0000-0002-4744-5109
Article History
Received: 9 August 2018
Revised: 26 December 2018
Accepted: 31 December 2018
First Online: 24 January 2019
Compliance with ethical standards
:
: AMR is involved in the clinical development of eltrombopag for the treatment of aplastic anemia, serving as Principal Investigator of a phase III trial (NCT02099747), as a member of an advisory board and as a consultant for Novartis; AMR has also received lecture fees from Novartis. The paper describes an off-label use of eltrombopag. The remaining authors declare that they have no conflict of interest.